Darodipine (PY 108-068, PY-108068) is a potent calcium channel antagonist.
Treatment with darodipine increases the number and the average length of alkaline phosphatase-reactive capillaries and reduces the intercapillary distance and the diameter of cerebral capillaries in old rats. The pericapillary microrenvironment of the Ammon's horn is the most sensitive to treatment with darodipine[1]. Darodipine may reduce neuronal cytoskeletal changes occurring in aging and in neurodegenerative disorders. A 6-month treatment (from the 18th to the 24th month of life) with an oral daily dose of 10 mg/kg of darodipine restores in part the expression of 200 kDa-NF subunit immunoreactivity in the cerebellar cortex[2].
[1]. Amenta F, et al. Effect of long-term treatment with the dihydropyridine-type calcium channel blocker darodipine(PY 108-068) on the cerebral capillary network in aged rats. Mech Ageing Dev. 1995 Jan 31;78(1):27-37. [2]. Vega JA, et al. Effect of treatment with the dihydropyridine-type calcium antagonist darodipine (PY 108-068) on the expression of neurofilament protein immunoreactivity in the cerebellar cortex of aged rats. Mech Ageing Dev. 1994 Aug;75(2):169-77.